Compare DexCom, Inc. (DXCM) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs New York Times Co — how do they compare? DexCom, Inc. trades at $77.86 (market cap $28.06B), while New York Times Co trades at $75.5 (market cap $12.18B). The key difference: DexCom, Inc. is far larger — about 2.3× New York Times Co's market cap, and New York Times Co pays a 1.22% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | NYT | |
|---|---|---|
Market Cap | $28.06B | $12.18B |
Sector | Health | Media |
52-Week High | $89.53 | $85.86 |
52-Week Low | $54.84 | $51.43 |
Enterprise Value | $27.03B | $11.57B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
The New York Times (NYT) trades at $72.98, down 2.75% today, with a neutral technical outlook and mixed analyst sentiment. Fundamentally, the company shows strong profitability with 51.12% gross margins and consistent earnings beats, though valuation multiples appear elevated. Recent news highlights legal challenges involving reporter subpoenas and ongoing copyright disputes with OpenAI.
Outlook remains cautiously optimistic with a $78 consensus price target representing 7% upside potential. Key opportunities include sustained digital subscription growth and margin expansion, while risks involve legal uncertainties and potential regulatory pressures. The stock offers defensive characteristics amid market volatility but faces near-term headwinds from legal proceedings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
